Literature DB >> 12160135

Suppression of matrix metalloproteinase activity by SI-27: detection by a new activity assay with S-2444, a specific chromogenic peptide.

Daizo Yoshida1, Kunihiro Watanabe, Masahiro Noha, Hiroshi Takahashi, Akira Teramoto.   

Abstract

We have previously reported on the anti-invasive and angiosuppressive effects of SI-27, an anti-matrix metalloproteinase (MMP) agent. The molecular mechanism of its anti-MMP action, however, has not yet been determined. The purpose of this study was to investigate the effects of SI-27 on MMP- 1, -2, -3, -9, and TIMP-1, -2 secreted by human glioma cell lines (U87MG, U251MG, U373MG, and Y98G). When cells were exposed to non-cytotoxic concentrations of SI-27 (preliminarily determined by the MTT assay), expressions of mRNAs for the enzymes was not inhibited. For an MMP activity assay, we employed the fact that active MMPs could cleave modified pro-urokinase to form active urokinase, which then acted on S-2444 peptide to create a chromogenic product. Secretion of all pro-MMPs from glioma cells was not significantly reduced by SI-27. However, activation of pro-MMPs was significantly inhibited in a dose-dependent manner ((IC50 values for MMP-2; U87MG, 3.5 microg/ml; U25 IMG, 4.2 microg/ml; U373MG, 4.8 microg/ml; Y98G, 4.0 degreesg/ml); (IC50 values for MMP-9; 251MG, 7.2 microg/ml, U373MG, 2.8 microg/ml). In addition, active MMPs were not inhibited by SI-27. These findings were supported by zymographic analysis and by collagenolysis assay data. TIMP-1 and -2 were also not inactivated by SI-27. These findings suggest that SI-27 targets the activation process of pro-MMP. S-2444, a specific chromogenic peptide, was useful for quantitative analysis of the activity of MMP subtypes in this study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12160135     DOI: 10.1023/a:1015894513482

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

Review 1.  The regulation of neovascularization of matrix metalloproteinases and their inhibitors.

Authors:  M A Moses
Journal:  Stem Cells       Date:  1997       Impact factor: 6.277

Review 2.  Matrix metalloproteinases: a review.

Authors:  H Birkedal-Hansen; W G Moore; M K Bodden; L J Windsor; B Birkedal-Hansen; A DeCarlo; J A Engler
Journal:  Crit Rev Oral Biol Med       Date:  1993

3.  Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.

Authors:  D R Shalinsky; J Brekken; H Zou; C D McDermott; P Forsyth; D Edwards; S Margosiak; S Bender; G Truitt; A Wood; N M Varki; K Appelt
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

4.  The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells.

Authors:  S Wylie; I C MacDonald; H J Varghese; E E Schmidt; V L Morris; A C Groom; A F Chambers
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

5.  MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate.

Authors:  R Hanemaaijer; C F Sier; H Visser; L Scholte; N van Lent; K Toet; K Hoekman; J H Verheijen
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

6.  Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma.

Authors:  T Kurizaki; M Toi; T Tominaga
Journal:  Oncol Rep       Date:  1998 May-Jun       Impact factor: 3.906

7.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas.

Authors:  A Nakano; E Tani; K Miyazaki; Y Yamamoto; J Furuyama
Journal:  J Neurosurg       Date:  1995-08       Impact factor: 5.115

8.  Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors.

Authors:  J S Rao; P A Steck; S Mohanam; W G Stetler-Stevenson; L A Liotta; R Sawaya
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

9.  Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: a parallel investigation by semiquantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry.

Authors:  G Keyszer; A Redlich; T Häupl; J Zacher; M Sparmann; U Engethüm; S Gay; G R Burmester
Journal:  Arthritis Rheum       Date:  1998-08

10.  Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.

Authors:  P A Forsyth; H Wong; T D Laing; N B Rewcastle; D G Morris; H Muzik; K J Leco; R N Johnston; P M Brasher; G Sutherland; D R Edwards
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more
  2 in total

1.  Inhibition of cell invasion by indomethacin on glioma cell lines: in vitro study.

Authors:  Maode Wang; Daizo Yoshida; Shouxun Liu; Akira Teramoto
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

2.  Drug-induced apoptosis by a matrix metalloproteinase inhibitor, SI-27 on human malignant glioma cell lines; in vitro study.

Authors:  Ryuzaburo Kanazawa; Daizo Yoshida; Hiroshi Takahashi; Yuichi Sugisaki; Satoru Suzuki; Akira Teramoto
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.